Immuneering (IMRX) Amortizatization of Intangibles (2020 - 2026)
Immuneering (IMRX) recorded quarterly Amortizatization of Intangibles of $404723.0 in Q1 2026, up 5431.27% quarter-over-quarter from $7317.0 in Q4 2025, and up 386.55% on a YoY basis from $83183.0 in Q1 2025.
Immuneering (IMRX) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Immuneering's Amortizatization of Intangibles history runs 7 years deep, the most recent figure standing at $404723.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 386.55% year-over-year to $404723.0; the TTM figure through Mar 2026 stood at $426674.0 (up 138.33% YoY), while the FY2025 annual figure was $29267.0, down 91.09% from the prior year.
- Amortizatization of Intangibles was $404723.0 for Q1 2026 at Immuneering, up from $7317.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $404723.0 in Q1 2026 to a low of $7316.0 in Q4 2022.
- Historically, Amortizatization of Intangibles has averaged $54969.2 across 5 years, with a median of $7317.0 in 2022.
- The sharpest annual moves came in 2023 and 2025: Amortizatization of Intangibles soared 1205.52% in 2023, then slumped 90.99% in 2025.
- A 5-year view of Amortizatization of Intangibles shows it stood at $7316.0 in 2022, then jumped by 1104.83% to $88145.0 in 2023, then dropped by 7.87% to $81212.0 in 2024, then plunged by 90.99% to $7317.0 in 2025, then jumped by 5431.27% to $404723.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $404723.0 (Q1 2026), $7317.0 (Q4 2025), and $7317.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Immuneering | 255.40 Mn | 255.40 Mn | - | 404,723.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 404,723.00 |
| Mar 31, 2026 | 404,723.00 |
| Dec 31, 2025 | 7,317.00 |
| Dec 31, 2025 | 7,317.00 |
| Sep 30, 2025 | 7,317.00 |
| Sep 30, 2025 | 7,317.00 |
| Jun 30, 2025 | 7,317.00 |
| Jun 30, 2025 | 7,317.00 |
| Mar 31, 2025 | 83,183.00 |
| Mar 31, 2025 | 83,183.00 |
| Dec 31, 2024 | 81,212.00 |
| Dec 31, 2024 | 81,212.00 |
| Sep 30, 2024 | 7,317.00 |
| Sep 30, 2024 | 7,317.00 |
| Jun 30, 2024 | 7,317.00 |
| Jun 30, 2024 | 7,317.00 |
| Mar 31, 2024 | 90,155.00 |
| Mar 31, 2024 | 90,155.00 |
| Dec 31, 2023 | 88,145.00 |
| Dec 31, 2023 | 88,145.00 |